Redefining Precision Medicine with Smarter Therapies
Our Vue63 platform transforms unique cancer enzymes—like SULT1A1—into activation switches, creating therapies that work only where they’re needed.
Market Problem
Selectivity Remains the Bottleneck
Despite advances in targeted therapies, most oncology drugs rely on systemic exposure, leading to dose-limiting toxicity and narrow therapeutic windows.
Platform Advantage
Activation-Based Differentiation
Vue63 shifts selectivity upstream by using tumor-associated enzyme activity to determine where a therapy becomes active—rather than relying solely on delivery or mutations.
De-Risked Execution
SULT1A1-Guided Precision
Elevated SULT1A1 expression in multiple aggressive cancers enables biomarker-driven patient selection, improving therapeutic index and development efficiency.
A platform designed to improve efficacy, reduce toxicity, and scale across multiple oncology indications.
A platform designed to improve efficacy, reduce toxicity, and scale across multiple oncology indications.
Management Team
Vyu’s leadership team comprises dedicated innovators with decades of collective experience in drug discovery, development, and company building.
-
Ravi Anchoori
FOUNDER
-
Yung Nien Chang
Chief Operating Officer
-
Richard Roden
Scientific Advisor
-
Rueyshyang Soong, MD
Chief Medical Officer
-
Bill MACKIN
Regulatory Consultant
-
Vidyasagar Anchoori
CMC consultant